Post Reply
21-40 of 809
Next medical in play??!!!
ykjuay ( Date: 31-Mar-2022 16:36) Posted:
|
watch out for its volume....support at 0.14
worth a bet at 0.014
Watch Asiamedic closely. Time to bounce. Sellers dried
Healthway 37 cleared yesterday to close 38
Asiamedic should play catch up. Watch this one closely . DYODD
Asiamedic should play catch up. Watch this one closely . DYODD
AnthonyWoodPeck ( Date: 17-Nov-2021 09:07) Posted:
|
Hidden buyers for Asiamedic 17.
Hidden buyers got Healthway 35.
Looks like the bounce is coming.
DYODD
Hidden buyers got Healthway 35.
Looks like the bounce is coming.
DYODD
any news today?
Can start watching AsiaMedic
Hidden buyers keep coming $0.019.
Should be coming. DYODD
$0.019 should be safe to collect
Hidden buyers keep coming $0.019.
Should be coming. DYODD
$0.019 should be safe to collect
look set to gap up 2-3pips from sinopharm vaccine news.
a bit late into the game. many other groups have already started earlier.
SINOPHARM COVID-19 VACCINE TO BE ADMINISTERED IN ASIAMEDIC CLINICS FROM 30 SEPTEMBER 2021
https://links.sgx.com/1.0.0/corporate-announcements/NK13263K1NRAMLP8/685292_AML_Sinopharm_Covid-19_Vaccine_20210930.pdf
SINOPHARM COVID-19 VACCINE TO BE ADMINISTERED IN ASIAMEDIC CLINICS FROM 30 SEPTEMBER 2021
https://links.sgx.com/1.0.0/corporate-announcements/NK13263K1NRAMLP8/685292_AML_Sinopharm_Covid-19_Vaccine_20210930.pdf
Yes. Seems like it
tankoksee ( Date: 27-Jul-2021 09:19) Posted:
|
coming ahh
no interest? same as diagnostic test kits?
another cfm?
this co oso doing covid testing kit?
TobyRun ( Date: 26-Nov-2020 10:56) Posted:
|
Happy 牛 Year to all.
Wish all good health and good wealth
Any news on this counter? Was moving before closing today.
https://links.sgx.com/1.0.0/corporate-announcements/A0HSW2C757GQ81T7/3f66114ec1eeeec11ddd898fb1f7719f349afc1fe4c7fab8b6c19d8e442336bf
The Board of Directors (the &ldquo Board&rdquo or the &ldquo Directors&rdquo ) of AsiaMedic Limited (the " Company" and together with its subsidiaries, the &ldquo Group&rdquo )) wishes to announce that the issued and paidup share capital of The Orchard Imaging Company Pte Ltd (&ldquo TOIC&rdquo ), a wholly-owned subsidiary of the Company, has been increased from S$500,000 to S$8,000,000 by way of allotment and issue of 7,500,000 new ordinary shares at S$1 each to the Company. The aforesaid allotment and issue of shares is pursuant to the capitalisation of inter-company loan and payables of S$7,500,000 owing by TOIC to the Company. The loan and payables to TOIC were for capital expenditure and working capital purposes and the Company is increasing the issued and paid-up share capital of TOIC to strengthen its financial position. The effect on the issued and paid-up share capital of TOIC before and after the aforesaid capitalisation is as follows: Issued and paid-up share capital before capitalisation Number of issued shares before capitalisation Issued and paid-up share capital after capitalisation Number of issued shares after capitalisation S$500,000 500,000 S$8,000,000 8,000,000 TOIC remains a wholly-owned subsidiary of the Company after the capitalisation. The capitalisation is not expected to have any material impact on the consolidated net tangible assets per share or earnings per share of the Group for the current financial year ending 31 December 2020. None of the Directors, controlling shareholders or substantial shareholders of the Company has any interest, directly or indirectly, in the aforesaid capitalisation, save through his shareholdings (if any) in the Company.
Meaning?
The Board of Directors (the &ldquo Board&rdquo or the &ldquo Directors&rdquo ) of AsiaMedic Limited (the " Company" and together with its subsidiaries, the &ldquo Group&rdquo )) wishes to announce that the issued and paidup share capital of The Orchard Imaging Company Pte Ltd (&ldquo TOIC&rdquo ), a wholly-owned subsidiary of the Company, has been increased from S$500,000 to S$8,000,000 by way of allotment and issue of 7,500,000 new ordinary shares at S$1 each to the Company. The aforesaid allotment and issue of shares is pursuant to the capitalisation of inter-company loan and payables of S$7,500,000 owing by TOIC to the Company. The loan and payables to TOIC were for capital expenditure and working capital purposes and the Company is increasing the issued and paid-up share capital of TOIC to strengthen its financial position. The effect on the issued and paid-up share capital of TOIC before and after the aforesaid capitalisation is as follows: Issued and paid-up share capital before capitalisation Number of issued shares before capitalisation Issued and paid-up share capital after capitalisation Number of issued shares after capitalisation S$500,000 500,000 S$8,000,000 8,000,000 TOIC remains a wholly-owned subsidiary of the Company after the capitalisation. The capitalisation is not expected to have any material impact on the consolidated net tangible assets per share or earnings per share of the Group for the current financial year ending 31 December 2020. None of the Directors, controlling shareholders or substantial shareholders of the Company has any interest, directly or indirectly, in the aforesaid capitalisation, save through his shareholdings (if any) in the Company.
Meaning?
Surging. Huat to all
Dyodd